These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10719423)

  • 1. [Serum chromogranin A in prostate cancer. Preliminary results].
    Reale MG; Marchei GG; Boccia S; Cristofoletti C; Caporossi E; Marchei M; Izzo P; Marchei P
    Minerva Med; 1999; 90(7-8):221-3. PubMed ID: 10719423
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum chromogranin A in prostate cancer].
    Akakura K
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():160-4. PubMed ID: 12599564
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
    Yashi M; Tokue A
    J Urol; 2003 Jun; 169(6):2305; author reply 2305. PubMed ID: 12771784
    [No Abstract]   [Full Text] [Related]  

  • 4. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
    Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
    Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
    Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
    Leibovitch I; Pinthus Y; Sella BA; Ramon J
    Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A; Di Silverio F
    Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum chromogranin A in monitoring metastatic prostate cancer patients.
    Tarle M
    Anticancer Res; 1999; 19(6C):5663-6. PubMed ID: 10697637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
    Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
    Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chromogranin-A (CgA) in prostate cancer.
    Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
    Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer.
    Reis LO; Vieira LF; Zani EL; Denardi F; de Oliveira LC; Ferreira U
    J Investig Med; 2010 Dec; 58(8):957-60. PubMed ID: 20818262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 19. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
    Tarle M; Ahel MZ; Kovacić K
    Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Endocrine differentiated prostate cancer. Histology and immunohistochemistry].
    Helpap B; Oehler U; Bollmann R
    Pathologe; 1990 Jan; 11(1):18-24. PubMed ID: 1690418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.